Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Assessing the Effect of GS300 on Nonalcoholic Fatty Liver Disease

NCT04887766 is registered in ClinicalTrials.gov with Gelesis, Inc. as lead sponsor.

NCT NCT04887766
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04887766 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Assessing the Effect of GS300 on Nonalcoholic Fatty Liver Disease
Lead sponsor
Gelesis, Inc.
Phase
Not applicable
Overall status
Unknown status
Start date
July 1, 2022
Completion date
December 31, 2023
Enrollment
250 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

nonalcoholic fatty liver, weight loss